IL287120B2 - Substituted 5-(trifluoromethyl)pyrimidin-2-yl)amino)-1h-pyrazol-1-yl)cyclopropanecarboxamide and pharmaceutical compositions comprising them for use in treating cancer - Google Patents
Substituted 5-(trifluoromethyl)pyrimidin-2-yl)amino)-1h-pyrazol-1-yl)cyclopropanecarboxamide and pharmaceutical compositions comprising them for use in treating cancerInfo
- Publication number
- IL287120B2 IL287120B2 IL287120A IL28712021A IL287120B2 IL 287120 B2 IL287120 B2 IL 287120B2 IL 287120 A IL287120 A IL 287120A IL 28712021 A IL28712021 A IL 28712021A IL 287120 B2 IL287120 B2 IL 287120B2
- Authority
- IL
- Israel
- Prior art keywords
- compound
- pharmaceutically acceptable
- mixture
- disease
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962832775P | 2019-04-11 | 2019-04-11 | |
| PCT/US2020/027742 WO2020210684A1 (en) | 2019-04-11 | 2020-04-10 | Compounds, compositions and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL287120A IL287120A (en) | 2021-12-01 |
| IL287120B1 IL287120B1 (en) | 2025-02-01 |
| IL287120B2 true IL287120B2 (en) | 2025-06-01 |
Family
ID=72752101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL287120A IL287120B2 (en) | 2019-04-11 | 2020-04-10 | Substituted 5-(trifluoromethyl)pyrimidin-2-yl)amino)-1h-pyrazol-1-yl)cyclopropanecarboxamide and pharmaceutical compositions comprising them for use in treating cancer |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US12358896B2 (https=) |
| EP (1) | EP3953348B1 (https=) |
| JP (1) | JP7623294B2 (https=) |
| KR (1) | KR20210151887A (https=) |
| CN (1) | CN113939294A (https=) |
| AR (1) | AR118641A1 (https=) |
| AU (1) | AU2020272045B2 (https=) |
| BR (1) | BR112021020027A2 (https=) |
| CA (1) | CA3136447A1 (https=) |
| DK (1) | DK3953348T3 (https=) |
| EA (1) | EA202192530A1 (https=) |
| ES (1) | ES3018383T3 (https=) |
| IL (1) | IL287120B2 (https=) |
| MA (1) | MA55624A (https=) |
| MX (1) | MX2021012392A (https=) |
| SG (1) | SG11202111058XA (https=) |
| TW (1) | TWI851710B (https=) |
| WO (1) | WO2020210684A1 (https=) |
| ZA (1) | ZA202107499B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112088003B (zh) | 2017-12-20 | 2023-10-13 | 戴纳立制药公司 | 制备嘧啶基-4-氨基吡唑化合物的工艺 |
| EP4238975A4 (en) * | 2020-10-29 | 2024-06-12 | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | SUBSTITUTED DIARYLAMINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, MANUFACTURING PROCESS THEREOF AND USE THEREOF |
| CN116120291B (zh) * | 2023-04-11 | 2023-06-30 | 英矽智能科技(上海)有限公司 | 吲唑类化合物及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2638031T3 (https=) | 2010-11-10 | 2018-03-10 | ||
| SMT202100699T1 (it) | 2016-06-16 | 2022-01-10 | Denali Therapeutics Inc | Pirimidin-2-ilammino-1h-pirazoli come inibitori di lrrk2 per l'uso nel trattamento di disturbi neurodegenerativi |
| WO2018217946A1 (en) | 2017-05-24 | 2018-11-29 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| CN112088003B (zh) | 2017-12-20 | 2023-10-13 | 戴纳立制药公司 | 制备嘧啶基-4-氨基吡唑化合物的工艺 |
-
2020
- 2020-04-08 AR ARP200101008A patent/AR118641A1/es unknown
- 2020-04-10 US US17/602,480 patent/US12358896B2/en active Active
- 2020-04-10 SG SG11202111058XA patent/SG11202111058XA/en unknown
- 2020-04-10 CN CN202080041217.0A patent/CN113939294A/zh active Pending
- 2020-04-10 IL IL287120A patent/IL287120B2/en unknown
- 2020-04-10 JP JP2021559818A patent/JP7623294B2/ja active Active
- 2020-04-10 TW TW109112173A patent/TWI851710B/zh active
- 2020-04-10 EP EP20787582.4A patent/EP3953348B1/en active Active
- 2020-04-10 ES ES20787582T patent/ES3018383T3/es active Active
- 2020-04-10 WO PCT/US2020/027742 patent/WO2020210684A1/en not_active Ceased
- 2020-04-10 CA CA3136447A patent/CA3136447A1/en active Pending
- 2020-04-10 DK DK20787582.4T patent/DK3953348T3/da active
- 2020-04-10 MX MX2021012392A patent/MX2021012392A/es unknown
- 2020-04-10 MA MA055624A patent/MA55624A/fr unknown
- 2020-04-10 BR BR112021020027A patent/BR112021020027A2/pt unknown
- 2020-04-10 KR KR1020217036412A patent/KR20210151887A/ko active Pending
- 2020-04-10 AU AU2020272045A patent/AU2020272045B2/en active Active
- 2020-04-10 EA EA202192530A patent/EA202192530A1/ru unknown
-
2021
- 2021-10-05 ZA ZA2021/07499A patent/ZA202107499B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3953348A1 (en) | 2022-02-16 |
| CN113939294A (zh) | 2022-01-14 |
| TWI851710B (zh) | 2024-08-11 |
| EP3953348B1 (en) | 2024-12-18 |
| ZA202107499B (en) | 2022-06-29 |
| JP2022526015A (ja) | 2022-05-20 |
| ES3018383T3 (es) | 2025-05-16 |
| JP7623294B2 (ja) | 2025-01-28 |
| CA3136447A1 (en) | 2020-10-15 |
| SG11202111058XA (en) | 2021-11-29 |
| IL287120B1 (en) | 2025-02-01 |
| EP3953348A4 (en) | 2023-01-18 |
| TW202104213A (zh) | 2021-02-01 |
| EA202192530A1 (ru) | 2022-03-15 |
| AR118641A1 (es) | 2021-10-20 |
| WO2020210684A1 (en) | 2020-10-15 |
| AU2020272045B2 (en) | 2026-01-15 |
| KR20210151887A (ko) | 2021-12-14 |
| AU2020272045A1 (en) | 2021-10-28 |
| MX2021012392A (es) | 2021-11-12 |
| MA55624A (fr) | 2022-02-16 |
| US12358896B2 (en) | 2025-07-15 |
| US20220220094A1 (en) | 2022-07-14 |
| IL287120A (en) | 2021-12-01 |
| DK3953348T3 (da) | 2025-03-17 |
| BR112021020027A2 (pt) | 2021-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11840529B2 (en) | Substituted pyrimidines as LRKK2 inhibitors | |
| KR102843750B1 (ko) | 신경퇴행성 장애의 치료에서 사용하기 위한 lrrk2 저해제로서 피리미딘-2-일아미노-1h-피라졸 | |
| US10709692B2 (en) | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) | |
| JP2025520934A (ja) | Ｐｒｍｔ５阻害剤及びその使用 | |
| ES2445791T3 (es) | Compuestos hetererocíclicos y su uso como inhibidores de la glucógeno sintasa cinasa 3 | |
| AU2016272258A1 (en) | Pyrido(3,4-d)pyrimidine derivative and pharmaceutically acceptable salt thereof | |
| EA019524B1 (ru) | СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ с-kit И PDGFR | |
| US20220153728A1 (en) | Compounds, compositions and methods | |
| KR20230004612A (ko) | 염증성 질병의 치료를 위한 치환된 피리딘 | |
| IL287120B2 (en) | Substituted 5-(trifluoromethyl)pyrimidin-2-yl)amino)-1h-pyrazol-1-yl)cyclopropanecarboxamide and pharmaceutical compositions comprising them for use in treating cancer | |
| TW201028398A (en) | Quinolone compound and pharmaceutical composition | |
| JP5756011B2 (ja) | グリコーゲン合成酵素キナーゼ３（ｇｓｋ−３）としての１−（７−（ヘキサヒドロピロロ［３，４−ｃ］ピロール−２（１ｈ）−イル）キノリン−４−イル）−３−（ピラジン−２−イル）尿素誘導体とその関連化合物 | |
| JP7288161B2 (ja) | 新規ジヒドロキナゾリノン系化合物又はその薬理学的に許容される塩、及び細胞増殖阻害剤 | |
| HK40069073B (en) | Compounds, compositions and methods | |
| HK40069073A (en) | Compounds, compositions and methods | |
| EA050027B1 (ru) | Соединения, композиции и способы | |
| JP5975122B2 (ja) | ［（４−ヒドロキシ−２−オキソ−１，２，５，６−テトラヒドロ−３−ピリジニル）カルボニル］グリシン化合物の結晶形及びそれらの製造方法 | |
| KR20260062950A (ko) | 3-(2-(디메틸아미노)에틸)-1h-인돌-4-일 유도체 |